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Currently, in general dentistry the most commonly used 
local anaesthetic agents are 2% lignocaine (Xylotox, Adcock 
Ingram; Xylesthesin, 3M) with 1:80000 adrenaline content, 
3% mepivicaine (Carbocaine) without a vasoconstrictor 
and 4% articaine (Ubistesin 3M) with either 1:100000 or 
1:200000 adrenaline concentration. 
The local anaesthetic molecule consists of three 
components: (a) lipophilic aromatic ring, (b) intermediate 
ester or amide chain, and (c) terminal amine.1 The aromatic 
ring improves lipid solubility.1–3 The nerve membrane consists 
of a double lipid layer and a protein layer and therefore 
the property of enhancing lipid solubility contributes to 
increased potency of the anaesthetic agent as more of 
the available drug can diffuse through the membrane. The 
benzene aromatic ring is replaced in articaine by a thiophene 
ring, which allows even greater lipid solubility and further 
penetration of an administered dose into the neurons. Local 
anaesthetics have protein-binding characteristics which 
determine the duration of anaesthesia. Affinity for plasma 
proteins corresponds to affinity for protein at the receptor 
site within sodium channels, prolonging the presence of 
the anaesthetic at the site of action. Agents that attach 
to the protein components of nerve membranes are also 
less likely to diffuse from the site of action and enter the 
systemic circulation, and therefore pose a lower systemic 
toxicity risk.2,5
The intermediate chain can be either an amide or ester 
group; in general ester -containing local anaesthetic 
solutions  are no longer packaged in dental cartridges.3 
However, articaine is unique in this regard. It is classified 
as an amide according to its intermediate linkage, but also 
contains an ester side chain on its aromatic ring.1,2,6 It is the 
only amide anaesthetic containing an ester group, allowing 
hydrolysis by blood cholinesterase (biotransformation in 
the plasma) as well as in the liver (by hepatic microsomal 
enzymes).1–3,6 As a result, articaine has a half-life of only 
20 minutes compared with 90 minutes for lignocaine that 
requires total hepatic clearance.3 Hence, articaine presents 
less risk for systemic toxicity during lengthy appointments 
when additional doses of anaesthetic are administered.2,3 
doSAge oF LocAL AnAeSthetIc
Dental cartridges generally contain two drugs, namely, a lo-
cal anaesthetic and a vasoconstrictor, each having its own 
dose limitations. Serum concentrations are related to the 
total dosage rather than the concentration of the solution, 
e.g. 2% or 4% local anaesthetic. Administering 20ml of 2% 
or 10ml of 4% (400mg) produces the same serum concen-
tration.2,3 Thus it is important to consider the dosage (mil-
ligrams) administered and not the volume (milliliters or car-
tridges) of the local anaesthetic administered. One should 
consider anaesthetic cartridges as containing 2ml and not 
1.8ml to simplify calculations, leading also to an overesti-
mation of the dosage, thereby promoting safety in limiting 
administration of the drug. Lignocaine 2% contains 36mg 
and articaine 4% contains 72mg of the drug per cartridge.
Each local anaesthetic has its own maximum recom-
mended dose (MDR), expressed in mg/kg. Unfortunately, 
the mg/kg MDR for each drug varies in the literature7 from 
4.4mg/kg8 to 6.6mg/kg.9 Recommended maximum doses 
for healthy adults (Table 1) for lignocaine 2% is 4.4mg/kg, 
for articaine 7mg/kg and for mepivicaine 6mg/kg with a 
ceiling dose approximate to those for a 70kg person.8,10 
Thus, the MDR of 2% lignocaine with adrenaline for a 
15kg child = 15kg x 4.4mg/kg = 66mg maximum dose of 
lignocaine. Since a lignocaine/cartridge contains 36mg of 
the drug this equates to 1.5 cartridges.7 A general con-
servative “rule of 10” may be used as a general guideline 
for maximum dosages i.e. one cartridge per 10kg body 
weight (up to a maximum of 70kgs). Thus, the MDR for a 
15kg child would be 1.5 cartridges lignocaine.
cLInIcAL eFFIcAcy oF ARtIcAIne veRSuS 
LIgnocAIne 
There seems to be conflicting research results regarding 
the advantage of 4% articaine over 2% lignocaine. It is 
difficult to demonstrate to a level of statistical significance 
(evidence-based medicine) in a clinical trial that 4% articaine 
is superior to any other amide local anaesthetic.11 
However, anecdotal reports claim that articaine 
works faster, 1. 
works better, 2. 
“I don’t miss as often,” and 3. 
“gets patients numb when other local anaesthetics 4. fail.”11 
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2% lignocaine and 4% articaine with 1:100000 adrenaline 
have similar properties for use in surgery and have 
demonstrated a good safety and tolerance profile.12 
On the other hand, articaine with 1:100000 adrenaline 
showed a higher success rate than lignocaine with 
1:100000 adrenaline for buccal infiltration of mandibular 
molars13,14 but not when administered in the attempt to 
anaesthetize teeth with irreversible pulpitis.15 The efficacy 
of 4% articaine with 1:100,000 adrenaline was similar to 2% 
lignocaine with 1:100,000 adrenaline for intra-ligamentary 
injections.16 In a study on patients with irreversible pulpitis 
the anaesthetic efficacies of articaine and lignocaine were 
similar for inferior alveolar nerve blocks.17–19
However, other studies have shown that infiltrations of 4% 
articaine with adrenaline offer better clinical performance 
than 2% lignocaine in terms of latency and duration 
of the anaesthetic effect, but have not demonstrated 
any statistically significant differences in anaesthetic 
efficacy.13,20 When the success of inferior alveolar nerve 
blocks were compared, articaine and lignocaine performed 
similarly.21 For infiltration articaine produced shorter 
onset and longer duration of pulpal anaesthesia than the 
lignocaine solution.22 Supplemental buccal infiltration with 
articaine was more effective than lignocaine in mandibular 
molars with irreversible pulpitis.23 This may be the result of 
a concentration effect or a greater diffusion of articaine. 
There was a high statistically significant difference 
between the articaine and lignocaine solutions when their 
efficacy was compared in maxillary buccal infiltrations in 
patients with irreversible pulpitis.24 The success of articaine 
after infiltration may be attributable to high lipid solubility 
and more molecules/ml injected when compared with 
lignocaine.3 For patients undergoing periodontal surgery, 
4% articaine anaesthetic with 1:100000 or 1:200000 
adrenaline provides excellent surgical pain control.25
In a systematic review articaine was shown to be more 
effective than lignocaine in providing anaesthetic success 
in the first molar region. The drugs appear to have similar 
adverse effect profiles.26,27 Another meta-analysis study 
concluded that articaine had a probability of achieving 
anaesthetic success superior to that of lignocaine, with an 
odds ratio of 2.44 (95% confidence interval [CI], 1.59–3.76; 
P < 0.0001).28 The odds ratio for articaine increased to 
3.81 (95 % CI, 2.71–5.36; P < 0.00001) when the authors 
analysed only the data for infiltration. There was weaker, 
but still significant, evidence of articaine being superior to 
lignocaine for mandibular block anaesthesia, with an odds 
ratio of 1.57 (95% CI, 1.12–2.21; P =0.009).28
SAFety oF 4% LocAL AnAeSthetIc
The apprehension that 4% articaine is related to adverse 
neurological effects like paraesthesia seem to stem from 
a retrospective study by Haas and Lennon.29,30 These au-
thors reported that generally the incidence of paraesthe-
sia is low but if paraesthesia does occur, it is significantly 
more likely to do so if either 4% articaine or prilocaine31,32 
has been injected. Hence, it has been suggested that the 
use of these agents for infiltration be limited and to rather 
reserve their use in nerve blocks for failed attempts with 
other agents.2,3 
Allegations that 4% local anaesthetics are associated 
with a greater risk of paraesthesia are based solely on 
anecdotal reports and have no scientific justification.6,11 
Linking 4% local anaesthetic with an increased risk of 
neurotoxicity, and recommending that  the use of articaine 
be avoided in mandibular nerve blocks is unjustified. 
Articaine is in fact a “safe and effective local anaesthetic” 
for Dentistry.11 To date, there has been no explanation that 
an inferior alveolar nerve block can, on a rare occasion, 
cause permanent nerve injury.33 Articaine is a safe and 
effective local anaesthetic drug to use in  Dentistry.4,6
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Lignocaine 2% 36mg 300mg 4.4mg/kg 1:80000 0.023mg
Mepivicaine 3% 54mg 300mg 6.0mg/kg - -
Articaine 4% 72mg 500mg 7.0mg/kg 1:100000 0.018mg
Articaine 4% 72mg 500mg 7.0mg/kg 1:200000 0.009mg
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